Allosteric NAMPT Activators for Metabolic and Neurological Disorders

Case ID:
UA21-191
Invention:

This invention relates to a novel method of increasing the catalytic activity of the enzyme, nicotinamide phosphoribosyltransferase (NAMPT), which in turn increases the production of nicotinamide mononucleotide (NMN) that is converted to nicotinamide adenine dinucleotide (NAD). This process to increase supply of NAD in the body is accomplished using small-molecule allosteric NAMPT activators. NAD supplementation has been shown to have benefits towards diseases of aging, metabolic disorders, and stroke.

Background:
Nicotinamide adenine dinucleotide (NAD) is a coenzyme that is central to metabolism and is essential for fortifying cells’ defense systems and regulating the body’s circadian rhythm. However, an individual's supply of NAD has been shown to decrease with age. With a decrease in NAD in the body, there are many associated health risks, such as neurodegeneration and metabolic dysregulation. Lower NAD levels can also be associated with stroke. For that reason, medications to increase one’s supply of NAD have been linked to many health benefits in the aging process. This product uses a novel pharmacological approach to restoring NAD by utilizing a new agent that activates the enzyme NAMPT, which is responsible for catalyzing the production of NAD.

Applications:

  • Anti-aging
  • Neurodegenerative disease prevention
  • Metabolic disease treatment
  • Supplement cell’s supply of NAD


Advantages:

  • More effective than current NAD+ supplements
  • Leverages benefits of current anti-aging treatments
Patent Information:
Contact For More Information:
Katherine Kuhns
Licensing Manager, UAHS-TLA
The University of Arizona
katiekuhns@email.arizona.edu
Lead Inventor(s):
Gregory Thatcher
Zhengnan Shen
Rui Xiong
Kiira Ratia
Yangfeng Li
Keywords: